- Ticker
- ADAP
- Price
- 0.47
- Stock movement up
- +0.02 (3.56%)
- Company name
- Adaptimmune Therapeutics Plc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Markedsverdi
- 76.87M
- Ent verdi
- 215.87M
- Pris/omsetning
- 2.83
- Pris/bok
- 0.94
- Utbytte avkastning
- -
- Utbytte vekst
- -
- Vekst år
- -
- FCF-utbetaling
- -
- Etterfølgende P/E
- -
- Fremtidig P/E
- -
- PEG
- -
- EPS-vekst
- -
- 1 års avkastning
- -80.94%
- 3 års avkastning
- -54.60%
- 5 års avkastning
- -38.94%
- 10 års avkastning
- -
Sist oppdatert: 2023-11-24
Adaptimmune Therapeutics plc (NASDAQ:NASDAQ:ADAP) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ETCompany ParticipantsJuli Miller – Investor...
8. november 2023
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from Adaptimmune Therapeutics plc (ADAP) stock at Seeking Alpha.
8. november 2023
iO Charts is a Seeking Alpha partner
UTBYTTE
ADAP betaler ikke utbytte
Get the latest news and real-time alerts from Adaptimmune Therapeutics plc (ADAP) stock at Seeking Alpha.
7. november 2023
iO Charts is a Seeking Alpha partner
Adaptimmune Therapeutics is a biotechnology company focused on developing cell therapies for solid tumors. Learn more about other promising therapies in development.
12. september 2023
iO Charts is a Seeking Alpha partner
VERDSETTELSE
Verdsettelsesforhold
Loading...
Verdsettelsesforhold-data
| Etterfølgende P/E | - |
| Pris til OCF | - |
| Pris til FCF | - |
| Pris til EBITDA | - |
| EV i forhold til EBITDA | - |
Verdsettelse (Salg/Bokført verdi)
Loading...
Verdsettelse (Salg/Bokført verdi) data
| Pris til omsetning | 2.83 |
| Pris til bok | 0.94 |
| EV i forhold til salg | 7.95 |
Adaptimmune Therapeutics plc (NASDAQ:NASDAQ:ADAP) Q2 2023 Results Conference Call August 9, 2023 8:00 AM ETCompany ParticipantsJuli Miller - Investor...
9. august 2023
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from Adaptimmune Therapeutics plc (ADAP) stock at Seeking Alpha.
9. august 2023
iO Charts is a Seeking Alpha partner
ØKONOMI
Per aksje
Loading...
Per aksje-data
| Gjeldende aksje antall | 165.30M |
| EPS (TTM) | -0.17 |
| FCF per aksje (TTM) | -0.17 |
Resultatregnskap
Loading...
Resultatregnskap-data
| Inntekter (TTM) | 27.15M |
| Bruttofortjeneste (TTM) | 27.15M |
| Driftsinntekter (TTM) | -136.72M |
| Netto inntekt (TTM) | -165.46M |
| EPS (TTM) | -0.17 |
| EPS (1 år fremover) | -0.52 |
Marginer
Loading...
Marginer-data
| Bruttomargin (TTM) | 100.00% |
| Driftsmargin (TTM) | -503.62% |
| Fortjenestemargin (TTM) | -609.46% |
Balanse
Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
| Kontanter | 108.03M |
| Netto fordringer | 7.43M |
| Samlede omløpsmidler | 255.37M |
| Goodwill | 0.00 |
| Immaterielle eiendeler | 442.00K |
| Eiendom, anlegg og utstyr | 0.00 |
| Sum eiendeler | 328.92M |
| Leverandørgjeld | 4.75M |
| Kortsiktig/nåværende langsiktig gjeld | 23.08M |
| Sum kortsiktig gjeld | 64.50M |
| Sum gjeld | 247.04M |
| Aksjonærenes egenkapital | 81.88M |
| Netto varige driftsmidler | 0.00 |
Kontantstrøm
Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
| Kontantstrøm fra drift (TTM) | -141.77M |
| Kapitalutgifter (TTM) | 29.50M |
| Fri kontantstrøm (TTM) | -171.26M |
| Utbetalt utbytte (TTM) | 0.00 |
Finansielle inntekter
Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
| Egenkapitalavkastning | -202.08% |
| Avkastning på eiendeler | -50.30% |
| Avkastning på investert kapital | -195.56% |
| Kontantavkastning på investert kapital | -202.43% |
Get the latest news and real-time alerts from Adaptimmune Therapeutics plc (ADAP) stock at Seeking Alpha.
8. august 2023
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from Adaptimmune Therapeutics plc (ADAP) stock at Seeking Alpha.
1. juni 2023
iO Charts is a Seeking Alpha partner
AKSJEINFORMASJON
Aksjediagram
Loading...
Aksjekurs-data
| Åpning | 0.45 |
| Daglig høy | 0.47 |
| Daglig lav | 0.43 |
| Daglig volum | 367K |
| Tidenes høyeste | 21.12 |
| 1 år analytikerestimat | 5.86 |
| Beta | 2.21 |
| EPS (TTM) | -0.17 |
| Utbytte per aksje | - |
| Ex-div dato | - |
| Neste dato for resultatpresentasjon | - |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| ADAP | S&P500 | |
| Nåværende prisfall fra toppnotering | -97.80% | -4.69% |
| Høyeste prisfall | -97.97% | -56.47% |
| Dato for høyeste fall | 20 Nov 2023 | 9 Mar 2009 |
| Gj.snittlig fall fra topp | -72.86% | -11.47% |
| Gj.snittlig tid til ny topp | 431 days | 13 days |
| Maks tid til ny topp | 2127 days | 1805 days |
Adaptimmune Therapeutics plc (NASDAQ:NASDAQ:ADAP) Q1 2023 Earnings Conference Call May 12, 2023 8:00 AM ETCompany ParticipantsJuli Miller - Head-Investor...
12. mai 2023
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from Adaptimmune Therapeutics plc (ADAP) stock at Seeking Alpha.
12. mai 2023
iO Charts is a Seeking Alpha partner
SELSKAPSOPPLYSNINGER
Markedsverdi
76.87M
Markedsverdi kategori
Small-cap
Beskrivelse
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; co-development collaboration agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Ansatte
534
Nettsted
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Adrian Rawcliffe
Land
USA
By
Abingdon
Aksjetype
American depositary share
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
Get the latest news and real-time alerts from Adaptimmune Therapeutics plc (ADAP) stock at Seeking Alpha.
11. mai 2023
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from Adaptimmune Therapeutics plc (ADAP) stock at Seeking Alpha.
11. mai 2023
iO Charts is a Seeking Alpha partner
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Seeking AlphaPressemeldinger
ADAP is swapping 1.5117 of its shares for every TCRR share. Click to read how shareholders can lock in a big gain once the deal closes.
21. april 2023
Get the latest news and real-time alerts from Adaptimmune Therapeutics plc (ADAP) stock at Seeking Alpha.
18. april 2023
Get the latest news and real-time alerts from Adaptimmune Therapeutics plc (ADAP) stock at Seeking Alpha.
11. april 2023
Adaptimmune is down after merging with TCR2, while TCR2 is up. Read more to see why the merger with TCRR stock looks like a smart deal for ADAP stock.
26. mars 2023
Get the latest news and real-time alerts from Adaptimmune Therapeutics plc (ADAP) stock at Seeking Alpha.
23. mars 2023
Adaptimmune Therapeutics plc (NASDAQ:NASDAQ:ADAP) Q4 2022 Earnings Conference Call March 6, 2023 8:00 AM ETCompany ParticipantsJuli Miller - Head-Investor...
6. mars 2023
Get the latest news and real-time alerts from Adaptimmune Therapeutics plc (ADAP) stock at Seeking Alpha.
6. mars 2023
Get the latest news and real-time alerts from Adaptimmune Therapeutics plc (ADAP) stock at Seeking Alpha.
6. mars 2023
Get the latest news and real-time alerts from Adaptimmune Therapeutics plc (ADAP) stock at Seeking Alpha.
6. mars 2023
Get the latest news and real-time alerts from Adaptimmune Therapeutics plc (ADAP) stock at Seeking Alpha.
3. mars 2023
iO Charts is a Seeking Alpha partnerNeste side